Almac's New Headquarters Ready to Handle Controlled Substances
Almac’s new North American Headquarters facility can now handle packaging, storage, and distribution of Schedule I – V controlled substances. Situated in Souderton, PA, the facility is nearing the end of its phased transition fueled by a $120 million investment.
Occupying a total of 3980 square feet, storage for controlled materials is located in a highly secured temperature-monitored cage and vault. Both locations meet DEA requirements as well as provide substantially greater capacity.
Dave Setley, head of business development, reports that “the expanded storage and distribution of controlled drug product from the NAHQ further solidifies Almac's position as a leader in the clinical supply arena."
Almac’s facility growth has also allowed the company to offer a broad range of pharmaceutical development services from the U.S. headquarter site, all under one roof. This model mirrors the myriad services offered by the global headquarters in Northern Ireland. Clients can now carry out their trial supply services from the Souderton, PA, location as well as IWR/IVRS and analytical services if needed.
As the phased transition nears its end, Almac is working around the clock to make sure current projects continue without interruption. Almac invites existing and prospective clients to schedule tours of the facility or learn more by visiting www.almacgroup.com.
The Almac Group provides a range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.
The company employs more 3000 individuals and is headquartered in Craigavon, Northern Ireland. U.S. operations are based in Pennsylvania, North Carolina and California. Almac has now moved into its new $120m North American Headquarters located in Souderton, PA.